Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Anlotinib + SOX for Neoadjuvant AEG (TASTE)
NCT06396585Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and anlotinib in adenocarcinoma of the gastroesophageal junction, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Pathological Complete Response. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT06396585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06396585.